We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 45.00 | 65.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 55.00 | GBX |
Verona Pharma (VRP) Share Charts1 Year Verona Pharma Chart |
|
1 Month Verona Pharma Chart |
Intraday Verona Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/1/2025 | 14:05 | Verona Pharma: Developing first in class drugs for respiratory diseases | 1,576 |
| 30/10/2018 | 08:41 | Still time to look at Verona Pharma (VRP) | - |
| 01/8/2018 | 09:42 | Verona Pharma (VRP) One to Watch | - |
| 16/2/2015 | 17:30 | Verona Pharma with Charts & News | 11,549 |
| 24/11/2011 | 12:54 | verona pharma | 173 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 02/1/2025 15:31 by tradertrev Jefferies, who have a TP of $50, put out a note just before Christmas detailing feedback from pulmonologists they had surveyed about their prescribing experience with Ohtuvayre. Jefferies said this feedback suggested a peak US market share of 18% compared to their working assumpation of $1.5bn peak sales being less than 1.5% market share. Caveat to my considerable excitement about this is that the feedback sample is very small - only 8 doctors.The note also mentions the company's plan to pre-announce Q4 sales in January. I've now had that from two sources. |
Posted at 04/11/2024 13:59 by haroldthegreat Verona Pharma plcMon, November 4, 2024 at 7:00 AM GMT 8 min read In This Article: VRNA +3.09% Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company” “We are pleased to report an exceptionally strong start to the US launch of Ohtuvayre (ensifentrine) with healthcare professionals (HCPs) prescribing treatment across a broad range of chronic obstructive pulmonary disease (“COPD”) patients including background single, dual and nearly 50% on triple therapy,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “While it is still very early in the launch, we are extremely encouraged from the initial patient and HCP reports about Ohtuvayre’s potential to improve COPD symptoms regardless of COPD severity. This broad utilization across all patient types is consistent with market research and supports our belief that Ohtuvayre’s bronchodilator and non-steroidal anti-inflammatory activity is a significant advancement for COPD patients and can re-define the treatment paradigm. “In the third quarter, through the first seven weeks of launch, we recorded $5.6 million of net sales. We are excited by the continued acceleration as net sales for October exceeded the third quarter. More than 5,000 Ohtuvayre prescriptions were filled and more than 2,200 unique HCPs prescribed Ohtuvayre in just 12 weeks. “Alongside our successful Ohtuvayre launch, in the third quarter we initiated two Phase 2 clinical trials: a dose-ranging trial with glycopyrrolate, a long-acting muscarinic antagonist (“LAMA”) Third Quarter and Recent Highlights In August 2024, the Company launched Ohtuvayre for the maintenance treatment of COPD in the US. During the third quarter of 2024, the Company began enrollment in two new clinical programs: Phase 2 dose-ranging trial with glycopyrrolate, a LAMA, supporting a fixed-dose combination program for the maintenance treatment of COPD via a nebulizer. Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine in patients with NCFBE. Following the end of the third quarter, the Company received notification from the Centers for Medicare & Medicaid Services that its permanent, product-specific J-code for Ohtuvayre, J7601, has been accepted and will be effective January 1, 2025. The Company recently presented additional analyses of data from the Phase 3 ENHANCE trials with ensifentrine for the maintenance treatment of COPD at the European Respiratory Society International Congress 2024 and at CHEST Annual Meeting 2024 (“CHEST” In September 2024, the Company’s development partner in Greater China, Nuance Pharma, completed enrollment in its pivotal Phase 3 clinical trial evaluating ensifentrine for the maintenance treatment of COPD in China. Results from the trial are expected in 2025. Third Quarter 2024 Financial Results Cash position: Cash and cash equivalents at September 30, 2024 were $336.0 million (December 31, 2023: $271.8 million). The Company believes cash and cash equivalents at September 30, 2024, along with product sales and funding expected to become available under the $650 million strategic financings completed in May 2024, will enable Verona Pharma to fund planned operating expenses and capital expenditure requirements through at least the end of 2026. Product sales: Net sales were $5.6 million for the third quarter ended September 30, 2024 (Q3 2023: $0 million) related to product sales of Ohtuvayre. The Company received FDA approval on June 26, 2024 and the product was commercially available beginning in August 2024. Cost of sales: Cost of sales was $0.5 million for the third quarter ended September 30, 2024 (Q3 2023: $0 million), which included Ohtuvayre manufacturing costs incurred after US approval, inventory overhead costs and sales-based royalties due to Ligand. R&D Expenses: Research and development (“R&D̶ SG&A Expenses: Selling general and administrative expenses (“SG&AR Net loss: Net loss was $43.0 million for the third quarter ended September 30, 2024 (Q3 2023: $14.7 million). |
Posted at 21/10/2024 11:48 by haroldthegreat Ohtuvayre, a COPD maintenance treatment, costs $2,950 per month, or $35,400 per year:This price is almost three times higher than the Institute for Clinical Economic Review's (ICER) recommended valuation range of $7,500 to $12,700 per year. ICER is a non-profit that evaluates drug prices based on their health benefits and risks. I wonder what the co-pay is ? When was the drug launched in USA ? |
Posted at 01/1/2024 22:50 by haroldthegreat thank you Tim for the share chart. |
Posted at 09/5/2023 10:44 by tradertrev Cash and equivalents have risen from the $285m (pro-forma that included ATM issuance up to 3rd March 2023) at 31st December 2022, to $291m as at 31st March 2023. This suggests that further ATM issuance of $6m above Q2 cash costs (i.e. a total of $20m, or roughly 1m ADRs) were issued under the ATM facility between 3rd and 31st March 2023.This could explain some relative sluggishness in the share price over that period. There is no mention of ATM issuance in today's statement in relation to both the total cash and equivalents and the liquidity available to last until at least the end of 2025. This suggests to me that they may have stopped issuing further shares under the ATM facility, at least for the time being. This could help the shares move on a bit. |
Posted at 07/2/2023 07:04 by tradertrev The graph shows that the price has fallen back after a barnstormingly good year. Yesterday's rise is very close to breaking the short term downtrend.Don't understand your unchanged expectations Haff. Maybe holding the chart the right way up would help? |
Posted at 06/2/2023 09:58 by haff1 Not good from a TA perspective: lowering highs and lowering lows....the graph is indicating a fall!! So no change in VRP expectaions.... |
Posted at 22/12/2022 08:53 by tradertrev Harold - not hard facts, but I seem to recall that if you went back far enough on old UK charts you would see the equivalent of at least £20 per UK share. This was diluted many times by share issuance at ever decreasing prices. £20 per UK share would be the equivalent now of $133 per ADR (8 shares per ADR), although at more normal exchange rates back then (say $1.50) it would be more like $107.I suspect this is all rather academic however. |
Posted at 20/12/2022 10:59 by timbo003 I'll settle for that, not quite as good as ENHANCE2, as they just missed out on significance for reduction in exacerbation rate, but they are good enough, especially when you combine the data from the two studies and bingo, Clinically menaingful statistical significant reductions in exacerbations which everway you look at itI predict a blue day for the share price |
Posted at 09/8/2022 18:48 by haroldthegreat Tim perhaps you should remove the LSE VRP charts ? Looks like that the shares have flat lined . Today they have been given a shot of Viagra but like Viagra the effect on the share price is waning after a few hours ! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
